A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types

Axel Bex¹, Michael Jewett², Bryan Lewis³, E Jason Abel⁴, Laurence Albiges⁵, Stephanie A Berg⁶, Gennady Bratslavsky⁷, David Braun⁸, James Brugarolas⁹, Toni K Choueiri⁶, Antonio Finelli², Daniel George¹⁰, Naomi B Haas¹¹, A Ari Hakimi¹², Hans Hammers¹³, Michelle Hirsch¹⁴, Eric Jonasch¹⁵, Payal Kapur¹⁶, W Marston Linehan¹⁷, Viraj Master¹⁸, Bradley McGregor⁶, Rana R McKay¹⁹, Rohit Mehra²⁰, Sumantha Pal²¹, Susan Poteat³, Thomas B Powles²², Sabrina H Rossi²³, Daniel D Shapiro²⁴, Sabina Signoretti¹⁵, Eric A Singer²⁵, Chuck Stravin²⁶, Nizar Tannir¹⁵, Ulka Vaishampayan²⁷, Wenxin Xu⁶, Grant D Stewart²³

Affiliations

¹ Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK. Electronic address: a.bex@nki.nl.
² Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
³ KidneyCAN, Philadelphia, PA, USA.
⁴ Departments of Urology and Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
⁵ Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
⁶ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA.
⁸ Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
⁹ Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX, USA; Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
¹¹ Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹² Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
¹⁵ Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
¹⁷ Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
¹⁸ Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
¹⁹ University of California-San Diego, La Jolla, CA.
²⁰ Department of Pathology, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
²¹ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
²² Barts Cancer Institute and the Royal Free NHS Trust, Queen Mary University, London, UK.
²³ Department of Surgery, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
²⁴ Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
²⁵ Division of Urologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
²⁶ Patient advocate, Quincy, MA, USA.
²⁷ Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

PMID: 39855942
DOI: 10.1016/j.eururo.2025.01.007

Editorial

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types

Axel Bex et al. Eur Urol. 2025 Apr.

. 2025 Apr;87(4):385-389.

doi: 10.1016/j.eururo.2025.01.007. Epub 2025 Jan 23.

Authors

Affiliations

¹ Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK. Electronic address: a.bex@nki.nl.
² Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
³ KidneyCAN, Philadelphia, PA, USA.
⁴ Departments of Urology and Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
⁵ Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
⁶ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA.
⁸ Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
⁹ Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX, USA; Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
¹¹ Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹² Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Department of Internal Medicine (Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
¹⁵ Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
¹⁷ Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
¹⁸ Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
¹⁹ University of California-San Diego, La Jolla, CA.
²⁰ Department of Pathology, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
²¹ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
²² Barts Cancer Institute and the Royal Free NHS Trust, Queen Mary University, London, UK.
²³ Department of Surgery, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
²⁴ Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
²⁵ Division of Urologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
²⁶ Patient advocate, Quincy, MA, USA.
²⁷ Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

PMID: 39855942
DOI: 10.1016/j.eururo.2025.01.007

Abstract

Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are urgently needed for the development of adaptive perioperative immunotherapy strategies for patients with RCC at high risk of recurrence.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types

Affiliations

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous